Michael A Fifer
Overview
Explore the profile of Michael A Fifer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
2017
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Masri A, Sherrid M, Abraham T, Choudhury L, Garcia-Pavia P, Kramer C, et al.
J Card Fail
. 2024 Mar;
30(11):1439-1448.
PMID: 38493832
Background: This open-label phase 2 trial evaluated the safety and efficacy of aficamten in patients with nonobstructive hypertrophic cardiomyopathy (nHCM). Methods: Patients with symptomatic nHCM (left ventricular outflow tract obstruction...
12.
Yasuda R, Osawa I, Goto T, Hasegawa K, Fifer M, Tower-Rader A, et al.
Circ Rep
. 2024 Mar;
6(3):74-79.
PMID: 38464986
Alcohol septal ablation (ASA) and septal myectomy (SM) are 2 options for septal reduction therapy (SRT) to treat medication-resistant symptomatic obstructive hypertrophic cardiomyopathy (HCM). Because differences in mortality rates after...
13.
Akita K, Hasegawa K, Fifer M, Tower-Rader A, Jung J, Maurer M, et al.
Nutr Metab Cardiovasc Dis
. 2024 Feb;
34(6):1352-1360.
PMID: 38403486
Backgrounds And Aims: Hypertrophic cardiomyopathy (HCM) causes cardiac death through both sudden cardiac death (SCD) and death due to heart failure (HF). Although adipokines lead to adverse cardiac remodeling in...
14.
Lee C, Liang L, Hasegawa K, Maurer M, Tower-Rader A, Fifer M, et al.
J Card Fail
. 2023 Aug;
30(3):462-472.
PMID: 37562580
Background: Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy. A subset of patients experience major adverse cardiovascular events (MACEs), including arrhythmias, strokes and heart failure. However, the molecular mechanisms...
15.
Owens A, Masri A, Abraham T, Choudhury L, Rader F, Symanski J, et al.
J Card Fail
. 2023 Jul;
29(11):1576-1582.
PMID: 37473912
No abstract available.
16.
Lumish H, Liang L, Hasegawa K, Maurer M, Fifer M, Reilly M, et al.
Heart
. 2023 Jul;
109(24):1837-1843.
PMID: 37451849
Objective: Heart failure (HF) is one of the most common and lifestyle-limiting complications of hypertrophic cardiomyopathy (HCM). Prediction of worsening HF using clinical measures alone remains limited. Moreover, the mechanisms...
17.
Liang L, Hasegawa K, Maurer M, Reilly M, Fifer M, Shimada Y
Circ Heart Fail
. 2023 Jun;
16(6):e010010.
PMID: 37305994
Background: Hypertrophic cardiomyopathy (HCM) is caused by mutations in genes coding for proteins essential for myocardial contraction. However, it remains unclear through which signaling pathways these gene mutations mediate HCM...
18.
Bode W, Bode M, Zhao M, Palacios I, Sakhuja R, Fifer M, et al.
J Interv Card Electrophysiol
. 2023 Apr;
66(9):2071-2080.
PMID: 37043093
Background: The most common complication of alcohol septal ablation (ASA) is transient periprocedural high-grade AV block (HGAVB). To date, no long-term follow-up of cardiovascular implantable electronic device (CIED) utilization after...
19.
Sherrid M, Bernard S, Tripathi N, Patel Y, Modi V, Axel L, et al.
JACC Cardiovasc Imaging
. 2023 Jan;
16(5):591-605.
PMID: 36681586
Background: Apical left ventricular (LV) aneurysms in hypertrophic cardiomyopathy (HCM) are associated with adverse outcomes. The reported frequency of mid-LV obstruction has varied from 36% to 90%. Objectives: The authors...
20.
Maron M, Masri A, Choudhury L, Olivotto I, Saberi S, Wang A, et al.
J Am Coll Cardiol
. 2023 Jan;
81(1):34-45.
PMID: 36599608
Background: Left ventricular outflow tract (LVOT) obstruction is a major determinant of heart failure symptoms in obstructive hypertrophic cardiomyopathy (oHCM). Aficamten, a next-in-class cardiac myosin inhibitor, may lower gradients and...